Allure Of Apellis Enhanced By Stellar Launch Of Syfovre
First GA Treatment Off To Strong Start
Rival Iveric may be in the process of being bought by Astellas but that has done nothing to dampen interest in Apellis and its geographic atrophy treatment, Syfovre, which was only launched in March yet reached Q1 sales of over $18m.
